Summary
This document is a case study detailing the BMT CTN 1401 study, which was designed as a Phase II, multicenter trial investigating the efficacy of vaccination with Dendritic Cell/myeloma fusions combined with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant and lenalidomide maintenance therapy in patients with multiple myeloma. The primary objective was to compare the proportion of patients alive and in complete response one year post-transplant between those receiving the DC/myeloma vaccine and lenalidomide maintenance therapy versus those receiving lenalidomide maintenance therapy alone or with GM-CSF. The study enrolled 203 patients, with 140 undergoing transplantation. The document outlines the collaborative vaccine manufacturing process and the challenges faced in transitioning to a multicenter approach, which were addressed through training and compliance with standard operating procedures. Key data indicates that the vaccine was successfully generated for 93% of patients, although the study did not find a significant increase in complete response rates at one year.
